JP2017025090A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017025090A5 JP2017025090A5 JP2016198882A JP2016198882A JP2017025090A5 JP 2017025090 A5 JP2017025090 A5 JP 2017025090A5 JP 2016198882 A JP2016198882 A JP 2016198882A JP 2016198882 A JP2016198882 A JP 2016198882A JP 2017025090 A5 JP2017025090 A5 JP 2017025090A5
- Authority
- JP
- Japan
- Prior art keywords
- combination according
- combination
- nanoparticle composition
- administered
- taxane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002105 nanoparticle Substances 0.000 claims 17
- 229940123237 Taxane Drugs 0.000 claims 9
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 9
- 239000002777 nucleoside Substances 0.000 claims 7
- 229940127073 nucleoside analogue Drugs 0.000 claims 7
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 7
- 102000014914 Carrier Proteins Human genes 0.000 claims 6
- 108010078791 Carrier Proteins Proteins 0.000 claims 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 5
- 201000002528 pancreatic cancer Diseases 0.000 claims 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 102000009027 Albumins Human genes 0.000 claims 2
- 108010088751 Albumins Proteins 0.000 claims 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 229960002756 azacitidine Drugs 0.000 claims 1
- 229960002170 azathioprine Drugs 0.000 claims 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 1
- 229960004117 capecitabine Drugs 0.000 claims 1
- 229960002436 cladribine Drugs 0.000 claims 1
- 229960000684 cytarabine Drugs 0.000 claims 1
- -1 doxyfluridine Chemical compound 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims 1
- 229960001428 mercaptopurine Drugs 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 238000011146 sterile filtration Methods 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229960003087 tioguanine Drugs 0.000 claims 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65424505P | 2005-02-18 | 2005-02-18 | |
| US60/654,245 | 2005-02-18 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015092577A Division JP6513467B2 (ja) | 2005-02-18 | 2015-04-30 | 治療薬の組み合わせおよび投与の様式ならびに併用療法 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018050735A Division JP2018090643A (ja) | 2005-02-18 | 2018-03-19 | 治療薬の組み合わせおよび投与の様式ならびに併用療法 |
| JP2019195457A Division JP2020012005A (ja) | 2005-02-18 | 2019-10-28 | 治療薬の組み合わせおよび投与の様式ならびに併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017025090A JP2017025090A (ja) | 2017-02-02 |
| JP2017025090A5 true JP2017025090A5 (enExample) | 2017-08-24 |
| JP6685875B2 JP6685875B2 (ja) | 2020-04-22 |
Family
ID=36593193
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007556407A Active JP5769358B2 (ja) | 2005-02-18 | 2006-02-21 | 治療薬の組み合わせおよび投与の様式ならびに併用療法 |
| JP2012156721A Withdrawn JP2012193205A (ja) | 2005-02-18 | 2012-07-12 | 治療薬の組み合わせおよび投与の様式ならびに併用療法 |
| JP2013001664A Withdrawn JP2013064014A (ja) | 2005-02-18 | 2013-01-09 | 治療薬の組み合わせおよび投与の様式ならびに併用療法 |
| JP2014180852A Active JP6092824B2 (ja) | 2005-02-18 | 2014-09-05 | 治療薬の組み合わせおよび投与の様式ならびに併用療法 |
| JP2015092577A Active JP6513467B2 (ja) | 2005-02-18 | 2015-04-30 | 治療薬の組み合わせおよび投与の様式ならびに併用療法 |
| JP2016198882A Active JP6685875B2 (ja) | 2005-02-18 | 2016-10-07 | 治療薬の組み合わせおよび投与の様式ならびに併用療法 |
| JP2018050735A Pending JP2018090643A (ja) | 2005-02-18 | 2018-03-19 | 治療薬の組み合わせおよび投与の様式ならびに併用療法 |
| JP2019195457A Withdrawn JP2020012005A (ja) | 2005-02-18 | 2019-10-28 | 治療薬の組み合わせおよび投与の様式ならびに併用療法 |
Family Applications Before (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007556407A Active JP5769358B2 (ja) | 2005-02-18 | 2006-02-21 | 治療薬の組み合わせおよび投与の様式ならびに併用療法 |
| JP2012156721A Withdrawn JP2012193205A (ja) | 2005-02-18 | 2012-07-12 | 治療薬の組み合わせおよび投与の様式ならびに併用療法 |
| JP2013001664A Withdrawn JP2013064014A (ja) | 2005-02-18 | 2013-01-09 | 治療薬の組み合わせおよび投与の様式ならびに併用療法 |
| JP2014180852A Active JP6092824B2 (ja) | 2005-02-18 | 2014-09-05 | 治療薬の組み合わせおよび投与の様式ならびに併用療法 |
| JP2015092577A Active JP6513467B2 (ja) | 2005-02-18 | 2015-04-30 | 治療薬の組み合わせおよび投与の様式ならびに併用療法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018050735A Pending JP2018090643A (ja) | 2005-02-18 | 2018-03-19 | 治療薬の組み合わせおよび投与の様式ならびに併用療法 |
| JP2019195457A Withdrawn JP2020012005A (ja) | 2005-02-18 | 2019-10-28 | 治療薬の組み合わせおよび投与の様式ならびに併用療法 |
Country Status (25)
| Country | Link |
|---|---|
| US (11) | US8034375B2 (enExample) |
| EP (4) | EP3698783A1 (enExample) |
| JP (8) | JP5769358B2 (enExample) |
| KR (8) | KR101764375B1 (enExample) |
| CN (4) | CN103169729A (enExample) |
| AT (1) | ATE531365T1 (enExample) |
| AU (1) | AU2006213999B2 (enExample) |
| BR (1) | BRPI0607809A2 (enExample) |
| CA (3) | CA2598239C (enExample) |
| CY (4) | CY1112907T1 (enExample) |
| DK (3) | DK3248600T3 (enExample) |
| ES (3) | ES2678448T3 (enExample) |
| HU (2) | HUE038768T2 (enExample) |
| IL (4) | IL185288A (enExample) |
| LT (2) | LT2301531T (enExample) |
| LU (1) | LU92484I2 (enExample) |
| MX (3) | MX2007009960A (enExample) |
| NZ (2) | NZ560879A (enExample) |
| PL (3) | PL1853250T3 (enExample) |
| PT (3) | PT3248600T (enExample) |
| RU (2) | RU2452482C2 (enExample) |
| SG (1) | SG166775A1 (enExample) |
| SI (3) | SI3248600T1 (enExample) |
| WO (1) | WO2006089290A1 (enExample) |
| ZA (1) | ZA200707491B (enExample) |
Families Citing this family (203)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030133955A1 (en) * | 1993-02-22 | 2003-07-17 | American Bioscience, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US20070117862A1 (en) * | 1993-02-22 | 2007-05-24 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20070092563A1 (en) * | 1996-10-01 | 2007-04-26 | Abraxis Bioscience, Inc. | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| EP1023050B1 (en) * | 1997-06-27 | 2013-09-25 | Abraxis BioScience, LLC | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20030199425A1 (en) * | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
| BR122012021252B8 (pt) | 2002-09-06 | 2021-05-25 | Cerulean Pharma Inc | polímeros à base de ciclodextrina para o fornecimento de agentes terapêuticos ligados a eles por covalência |
| LT1585548T (lt) | 2002-12-09 | 2018-09-25 | Abraxis Bioscience, Llc | Farmakologinių agentų kompozicijos ir įvedimo būdai |
| PT1583562E (pt) | 2003-01-06 | 2011-09-19 | Angiochem Inc | Angiopep-1, compostos relacionados, e suas utilizações |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| HUE038768T2 (hu) | 2005-02-18 | 2018-11-28 | Abraxis Bioscience Llc | Terápiás szerek kombinációi, valamint beadásukra szolgáló módszerek, és kombinációs terápia |
| US20070166388A1 (en) * | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| JP5235662B2 (ja) * | 2005-06-16 | 2013-07-10 | ミリアド ジェネティクス， インコーポレイテッド | 薬学的組成物およびその使用 |
| RU2422143C2 (ru) | 2005-07-15 | 2011-06-27 | Анджиокем Инк. | Усиление действия противораковых агентов |
| DE102005039579B4 (de) * | 2005-08-19 | 2022-06-30 | Magforce Ag | Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen |
| CA2620389C (en) | 2005-08-31 | 2014-06-17 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| PT1931321T (pt) | 2005-08-31 | 2019-05-14 | Abraxis Bioscience Llc | Composições compreendendo agentes farmacêuticos pouco hidrossolúveis e agentes antimicrobianos |
| RU2010104916A (ru) * | 2006-08-16 | 2011-08-20 | Михаил В. Благосклонный (US) | Способ профилактики и лечения возрастных заболеваний |
| EP2056812A1 (en) * | 2006-08-31 | 2009-05-13 | Abraxis BioScience, LLC | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
| US20080280987A1 (en) * | 2006-08-31 | 2008-11-13 | Desai Neil P | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
| US8178564B2 (en) | 2006-11-06 | 2012-05-15 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8168662B1 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8168661B2 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8173686B2 (en) | 2006-11-06 | 2012-05-08 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| ES2700074T3 (es) * | 2006-12-14 | 2019-02-13 | Abraxis Bioscience Llc | Terapia para el cáncer de mama sobre la base del estado de los receptores hormonales con nanopartículas que comprenden taxano |
| JP2010516625A (ja) | 2007-01-24 | 2010-05-20 | インサート セラピューティクス， インコーポレイテッド | 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート |
| BRPI0808635B1 (pt) * | 2007-03-07 | 2022-06-07 | Abraxis Bioscience, Llc | Uso de uma composição farmacêutica compreendendo nanopartículas que compreendem rapamicina ou um seu derivado e uma proteína veículo, composição para uso em um método de tratamento de câncer em um indivíduo, forma de dosagem unitária para o referido tratamento, e kit |
| AU2015271950B2 (en) * | 2007-03-07 | 2017-09-28 | Abraxis Bioscience, Llc | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
| WO2008124824A1 (en) * | 2007-04-10 | 2008-10-16 | Myriad Genetics, Inc. | Dosages and methods for the treatment of cancer |
| AU2008236993A1 (en) * | 2007-04-10 | 2008-10-16 | Myrexis, Inc. | Method of treating brain cancer |
| EP2144886A4 (en) * | 2007-04-10 | 2012-10-03 | Myrexis Inc | METHOD OF TREATING MELANOMA |
| AU2008236997A1 (en) * | 2007-04-10 | 2008-10-16 | Myrexis, Inc. | Methods for treating cancer |
| WO2008124828A1 (en) * | 2007-04-10 | 2008-10-16 | Myriad Genetics, Inc. | Methods for treating vascular disruption disorders |
| WO2008137148A2 (en) | 2007-05-03 | 2008-11-13 | Abraxis Bioscience, Llc | Methods and compositions for treating pulmonary hypertension |
| WO2008140751A1 (en) * | 2007-05-11 | 2008-11-20 | Champions Biotechnology, Inc. | Human leiosarcoma and non small cell lung cancer lung xenograft models |
| US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| ES2435452T3 (es) * | 2007-06-01 | 2013-12-19 | Abraxis Bioscience, Llc | Métodos y composiciones para tratar un cáncer recurrente |
| US9545384B2 (en) * | 2007-06-04 | 2017-01-17 | Bend Research, Inc. | Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate |
| KR20100023862A (ko) * | 2007-06-22 | 2010-03-04 | 싸이도우스 엘엘씨. | 트윈 80을 함유하지 않은 도세탁셀의 용해 제제 |
| WO2009062138A1 (en) * | 2007-11-08 | 2009-05-14 | Virginia Tech Intellectual Properties, Inc. | Thiolated paclitaxels for reaction with gold nanoparticles as drug delivery agents |
| US9233078B2 (en) | 2007-12-06 | 2016-01-12 | Bend Research, Inc. | Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer |
| WO2009078755A1 (en) * | 2007-12-19 | 2009-06-25 | Ardenia Investments, Ltd. | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance |
| CA2753844A1 (en) * | 2008-03-05 | 2009-09-11 | Vicus Therapeutics, Llc | Compositions and methods for mucositis and oncology therapies |
| WO2009126401A1 (en) * | 2008-04-10 | 2009-10-15 | Abraxis Bioscience, Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
| PT2279008T (pt) * | 2008-04-18 | 2019-05-20 | Angiochem Inc | Composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e utilização |
| EP2695609B1 (en) | 2008-05-15 | 2019-12-11 | Celgene Corporation | Oral formulations of cytidine analogs and methods of use thereof |
| MX339014B (es) * | 2008-05-27 | 2016-05-09 | Oncolytics Biotech Inc | Modulacion de presion intersticial y suministro y distribucion viral oncolitica. |
| UA104147C2 (uk) * | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| CN102245636A (zh) | 2008-10-15 | 2011-11-16 | 安吉奥开米公司 | 用于药物递送的依托泊苷和多柔比星结合物 |
| CN102245642A (zh) | 2008-10-15 | 2011-11-16 | 安吉奥开米公司 | Glp-1激动剂的结合物及其用途 |
| BRPI0922689A2 (pt) | 2008-12-05 | 2018-11-06 | Angiochem Inc. | conjugados de neurotensina ou análogos de neurotensina e usos dos mesmos |
| AU2009324464B2 (en) * | 2008-12-11 | 2016-05-05 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| CN102300987A (zh) | 2008-12-17 | 2011-12-28 | 安吉奥开米公司 | 膜型-1基质金属蛋白抑制剂及其用途 |
| WO2010105172A1 (en) * | 2009-03-13 | 2010-09-16 | Abraxis Bioscience, Llc | Combination therapy with thiocolchicine derivatives |
| WO2010114770A1 (en) * | 2009-03-30 | 2010-10-07 | Cerulean Pharma Inc. | Polymer-agent conjugates, particles, compositions, and related methods of use |
| WO2010114768A1 (en) * | 2009-03-30 | 2010-10-07 | Cerulean Pharma Inc. | Polymer-epothilone conjugates, particles, compositions, and related methods of use |
| WO2010117668A1 (en) * | 2009-03-30 | 2010-10-14 | Cerulean Pharma Inc. | Polymer-agent conjugates, particles, compositions, and related methods of use |
| RS59896B1 (sr) | 2009-04-15 | 2020-03-31 | Abraxis Bioscience Llc | Kompozicije nanočestica bez priona i postupci povezani sa njima |
| ES2729261T3 (es) | 2009-04-20 | 2019-10-31 | Angiochem Inc | Tratamiento del cáncer de ovario utilizando un agente anticancerígeno conjugado con un análogo de Angiopep-2 |
| EP2437738B1 (en) * | 2009-06-05 | 2018-08-08 | Joan M. Caron | Methods and compositions for the treatment of cancer |
| JP5932642B2 (ja) | 2009-07-02 | 2016-06-08 | アンジオケム インコーポレーテッド | 多量体ペプチドコンジュゲートおよびその使用 |
| US9340697B2 (en) | 2009-08-14 | 2016-05-17 | Nano-C, Inc. | Solvent-based and water-based carbon nanotube inks with removable additives |
| KR20120053052A (ko) | 2009-08-25 | 2012-05-24 | 아브락시스 바이오사이언스, 엘엘씨 | 헤지호그 억제제 및 탁산의 나노입자 조성물로의 조합 요법 |
| MX2012003287A (es) * | 2009-09-18 | 2012-08-03 | Abraxis Bioscience Llc | Uso de la identificacion microambiental de sparc en el tratamiento del cancer. |
| US8912228B2 (en) | 2009-10-19 | 2014-12-16 | Scidose Llc | Docetaxel formulations with lipoic acid |
| US20110092579A1 (en) * | 2009-10-19 | 2011-04-21 | Scidose Llc | Solubilized formulation of docetaxel |
| US8541465B2 (en) * | 2009-10-19 | 2013-09-24 | Scidose, Llc | Docetaxel formulations with lipoic acid and/or dihydrolipoic acid |
| US7772274B1 (en) | 2009-10-19 | 2010-08-10 | Scidose, Llc | Docetaxel formulations with lipoic acid |
| US20130115295A1 (en) * | 2009-11-22 | 2013-05-09 | Qiang Wang | Rare Earth-Doped Up-Conversion Nanoparticles for Therapeutic and Diagnostic Applications |
| WO2011088149A2 (en) * | 2010-01-12 | 2011-07-21 | Prometheus Laboratories Inc. | Methods for predicting response of triple-negative breast cancer to therapy |
| CN104784121A (zh) | 2010-03-26 | 2015-07-22 | 阿布拉科斯生物科学有限公司 | 治疗肝细胞癌的方法 |
| US9393318B2 (en) * | 2010-03-29 | 2016-07-19 | Abraxis Bioscience, Llc | Methods of treating cancer |
| BR112012024590A2 (pt) | 2010-03-29 | 2016-05-31 | Abraxis Bioscience Inc | métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos |
| JP2013525285A (ja) * | 2010-04-08 | 2013-06-20 | サンフォード−バーナム メディカル リサーチ インスティテュート | 化合物の送達を増強するための方法および組成物 |
| EP2382993A1 (en) | 2010-04-19 | 2011-11-02 | KTB Tumorforschungsgesellschaft mbH | Combination of drugs with protein-binding prodrugs |
| MY188911A (en) * | 2010-06-02 | 2022-01-13 | Abraxis Bioscience Llc | Methods of treating bladder cancer |
| CA2801190A1 (en) * | 2010-06-03 | 2011-12-08 | Abraxis Bioscience, Llc | Use of the sparc microenvironment signature in the treatment of cancer |
| KR20130088116A (ko) * | 2010-06-04 | 2013-08-07 | 아브락시스 바이오사이언스, 엘엘씨 | 췌장암의 치료 방법 |
| JP6031437B2 (ja) * | 2010-06-07 | 2016-11-24 | アブラクシス バイオサイエンス， エルエルシー | 増殖性疾患を処置するための組み合わせ療法 |
| KR101223484B1 (ko) * | 2010-10-05 | 2013-01-17 | 한국과학기술연구원 | 사람 혈청 알부민-ｓｉＲＮＡ 나노입자 전달체 |
| US8884027B2 (en) | 2010-10-22 | 2014-11-11 | University Of Rochester | Melampomagnolide B derivatives as antileukemic and cytotoxic agents |
| JP2014505666A (ja) * | 2010-11-18 | 2014-03-06 | ザ ジェネラル ホスピタル コーポレイション | 癌治療のための降圧剤の組成物および使用 |
| MX373096B (es) * | 2010-12-02 | 2020-04-27 | Oncolytics Biotech Inc | Formulaciones virales líquidas. |
| EA201390812A1 (ru) | 2010-12-02 | 2013-11-29 | Онколитикс Байотек Инк. | Лиофилизированные вирусные составы |
| KR102108959B1 (ko) * | 2011-04-28 | 2020-05-11 | 아브락시스 바이오사이언스, 엘엘씨 | 나노입자 조성물의 혈관내 전달 및 그의 용도 |
| AU2012253571A1 (en) | 2011-05-09 | 2014-01-09 | Mayo Foundation For Medical Education And Research | Cancer treatments |
| WO2013055874A2 (en) * | 2011-10-14 | 2013-04-18 | Genentech, Inc. | Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab |
| EA201490911A1 (ru) | 2011-11-01 | 2014-09-30 | Селджин Корпорейшн | Способы лечения злокачественных опухолей с использованием пероральных составов аналогов цитидина |
| WO2013085902A1 (en) | 2011-12-05 | 2013-06-13 | The University Of Texas M.D. | Combination therapy methods for treating an inflammatory breast cancer |
| WO2013090634A1 (en) | 2011-12-14 | 2013-06-20 | Abraxis Bioscience, Llc | Use of polymeric excipients for lyophilization or freezing of particles |
| GB201121924D0 (en) * | 2011-12-20 | 2012-02-01 | Fahy Gurteen Labs Ltd | Detection of breast cancer |
| EP2630971B8 (en) | 2012-02-21 | 2017-12-13 | Vergell Medical S.A. | Combinations of albumin-based drug delivery systems |
| SMT201800366T1 (it) | 2012-04-04 | 2018-09-13 | Halozyme Inc | Combinazione terapia con ialuronidasi e taxano mirato al tumore |
| US20150150995A1 (en) * | 2012-08-09 | 2015-06-04 | Pono Corporation | Conjugated anti-microbial compounds and conjugated anti-cancer compounds and uses thereof |
| PT2892535T (pt) * | 2012-09-04 | 2021-12-15 | Novartis Ag | Método de tratamento adjuvante do cancro |
| US10413606B2 (en) | 2012-10-01 | 2019-09-17 | Mayo Foundation For Medical Education And Research | Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies |
| WO2014055493A1 (en) | 2012-10-02 | 2014-04-10 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
| US9149455B2 (en) * | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| CA2890462A1 (en) | 2012-11-12 | 2014-05-15 | Ignyta, Inc. | Bendamustine derivatives and methods of using same |
| EP2919759A4 (en) | 2012-11-14 | 2016-07-20 | Ohio State Innovation Foundation | MATERIALS AND METHODS FOR THE TREATMENT OF GLIOBLASTOMES |
| EP2925718B1 (en) | 2012-11-30 | 2018-08-01 | Novomedix, LLC | Substituted biaryl sulfonamides and the use thereof |
| RU2689977C2 (ru) * | 2012-12-04 | 2019-05-30 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Применение эрибулина для лечения рака молочной железы |
| CN103333179B (zh) * | 2012-12-21 | 2017-06-16 | 百奥泰生物科技(广州)有限公司 | 类美登素衍生物及其制备方法和用途 |
| US20140199405A1 (en) * | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| US20140199404A1 (en) * | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on level of a nucleoside transporter |
| US9962452B2 (en) | 2013-02-04 | 2018-05-08 | Zhuhai Beihai Biotech Co., Ltd. | Soluble complexes of drug analogs and albumin |
| HK1218506A1 (zh) | 2013-02-11 | 2017-02-24 | 阿布拉科斯生物科学有限公司 | 治療黑素瘤的方法 |
| EP3698784A1 (en) * | 2013-03-12 | 2020-08-26 | Abraxis BioScience, LLC | Methods of treating lung cancer |
| US9376437B2 (en) | 2013-03-13 | 2016-06-28 | Oncoceutics, Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy |
| AU2014228386B2 (en) | 2013-03-13 | 2018-11-29 | Abraxis Bioscience, Llc | Methods of treatment of pediatric solid tumor |
| BR112015023256A2 (pt) | 2013-03-13 | 2017-07-18 | Oncoceutics Inc | terapia de combinação com 7-benzil-10-(2-metil-benzil)-2,6,7,8,9,10-hexaidroimidazol[1,2-a]pirido[4,3-d]pirimidin-5(3h)-ona. |
| US9688679B2 (en) | 2013-03-13 | 2017-06-27 | Oncoceutics, Inc. | 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy |
| NZ630213A (en) | 2013-03-14 | 2017-05-26 | Abraxis Bioscience Llc | Methods of treating bladder cancer |
| WO2014165842A2 (en) * | 2013-04-05 | 2014-10-09 | Igdrasol | Nanoparticle formulations in biomarker detection |
| KR101329646B1 (ko) * | 2013-05-02 | 2013-11-14 | 주식회사 지니스 | 표적지향증폭형 항암나노입자 및 이의 제조방법 |
| WO2015042234A1 (en) * | 2013-09-20 | 2015-03-26 | Igdrasol | Conditionally stable micelle compositions for cancer treatment including ovarian cancer |
| US20170065723A1 (en) * | 2013-09-27 | 2017-03-09 | Cerulean Pharma Inc. | Treatment of cancer |
| US10842969B2 (en) | 2013-10-25 | 2020-11-24 | Mercator Medsystems, Inc. | Systems and methods of treating malacia by local delivery of hydrogel to augment tissue |
| WO2015061748A1 (en) * | 2013-10-25 | 2015-04-30 | Mercator Medsystems, Inc. | Maintenance of bronchial patency by local delivery of cytotoxic, cytostatic, or anti-neoplastic agent |
| CN106163524B (zh) * | 2013-11-15 | 2019-11-08 | 昂克希尔迪克斯有限公司 | 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1H)-酮、其盐及应用方法 |
| FI20130341A7 (fi) | 2013-11-19 | 2015-05-20 | Oy Safemed Ltd | Huonosti vesiliukoisten lääkeaineiden kuljetus metalli-ioneilla tasapainotetun alfafetoproteiinin mukana |
| MX378409B (es) * | 2013-12-06 | 2025-03-10 | Novartis Ag | Regimen de dosificacion para un inhibidor selectivo alfa-isomorfo de fosfatidilinositol 3-quinasa. |
| NO2699580T3 (enExample) | 2014-01-24 | 2018-02-24 | ||
| EP2924022A1 (en) * | 2014-03-27 | 2015-09-30 | INDENA S.p.A. | Amorphous form of a thiocolchicine derivative |
| CN113318239B (zh) | 2014-06-13 | 2025-05-30 | 梅约医药教育及研究基金会 | 治疗淋巴瘤 |
| KR20210125603A (ko) | 2014-06-16 | 2021-10-18 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 골수종의 치료 |
| WO2015195634A1 (en) | 2014-06-17 | 2015-12-23 | Celgne Corporation | Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine |
| US9937259B2 (en) | 2014-06-27 | 2018-04-10 | Zhuhai Beihai Biotech Co., Ltd. | Abiraterone derivatives and non-covalent complexes with albumin |
| WO2015018380A2 (en) | 2014-07-03 | 2015-02-12 | Cspc Zhongqi Pharmaceutical Technology(Shijiazhuang)Co., Ltd. | Therapeutic nanoparticles and the preparation methods thereof |
| US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
| WO2016065283A1 (en) * | 2014-10-24 | 2016-04-28 | Bishop Alexander James Roy | Methods and compositions for enhancing chemotherapy |
| WO2016065139A1 (en) | 2014-10-24 | 2016-04-28 | Fl Therapeutics Llc | 3-substituted piperidine-2, 6-diones and non-covalent complexes with albumin |
| IL295286B2 (en) | 2015-01-30 | 2024-10-01 | Oncoceutics Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs thereof, and salts thereof and methods for their use in therapy |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| WO2016172515A1 (en) | 2015-04-23 | 2016-10-27 | Sanford Burnham Prebys Medical Discovery Institute | Targeted delivery system and methods of use therefor |
| CN107921143B (zh) | 2015-06-15 | 2021-11-19 | 安吉奥开米公司 | 用于治疗软脑膜癌病的方法 |
| CN116473964A (zh) | 2015-06-29 | 2023-07-25 | 阿布拉科斯生物科学有限公司 | 治疗上皮样细胞肿瘤的方法 |
| TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體－抗體組合物及其製造及使用方法 |
| TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
| EP3389720A1 (en) | 2015-12-18 | 2018-10-24 | The General Hospital Corporation | Polyacetal polymers, conjugates, particles and uses thereof |
| US11571469B2 (en) | 2016-01-07 | 2023-02-07 | Mayo Foundation For Medical Education And Research | Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression |
| US11351254B2 (en) | 2016-02-12 | 2022-06-07 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
| WO2017143092A1 (en) | 2016-02-19 | 2017-08-24 | Nant Holdings Ip, Llc | Methods of immunogenic modulation |
| AU2017238119A1 (en) | 2016-03-21 | 2018-10-11 | Mayo Foundation For Medical Education And Research | Methods for reducing toxicity of a chemotherapeutic drug |
| US11878061B2 (en) | 2016-03-21 | 2024-01-23 | Mayo Foundation For Medical Education And Research | Methods for improving the therapeutic index for a chemotherapeutic drug |
| AU2017281126A1 (en) | 2016-03-24 | 2018-10-04 | Nant Holdings Ip, Llc | Sequence arrangements and sequences for neoepitope presentation |
| US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| AU2017273495B2 (en) | 2016-06-02 | 2023-01-12 | Innopharmax, Inc. | Metronomic oral gemcitabine for cancer therapy |
| EP3478312A4 (en) | 2016-06-30 | 2020-07-29 | Nant Holdings IP, LLC | NANT CANCER VACCINE |
| WO2018026965A1 (en) | 2016-08-02 | 2018-02-08 | Isi Life Sciences, Inc. | Compositions and methods for detecting cancer cells in a tissue sample |
| KR20230006037A (ko) | 2016-08-05 | 2023-01-10 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 암 치료를 위한 변형된 항체-알부민 나노입자 복합체 |
| CN107714652B (zh) * | 2016-08-12 | 2021-03-02 | 四川科伦药物研究院有限公司 | 替西罗莫司白蛋白纳米组合物及其冻干制剂、制法和用途 |
| TWI787201B (zh) | 2016-08-31 | 2022-12-21 | 日商富士軟片股份有限公司 | 抗腫瘤劑、抗腫瘤效果增強劑及抗腫瘤用套組 |
| JP2019526579A (ja) | 2016-09-01 | 2019-09-19 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ | Ｔ細胞癌を標的とする為の方法及び組成物 |
| RU2019109211A (ru) | 2016-09-01 | 2020-10-01 | Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч | Композиции, содержащие носитель-pd-l1-связывающий агент для лечения рака |
| WO2018048958A1 (en) * | 2016-09-06 | 2018-03-15 | Mayo Foundation For Medical Education And Research | Paclitaxel-albumin-binding agent compositions and methods for using and making the same |
| EP3510048A1 (en) | 2016-09-06 | 2019-07-17 | Mayo Foundation for Medical Education and Research | Methods of treating pd-l1 expressing cancer |
| US11590098B2 (en) | 2016-09-06 | 2023-02-28 | Mayo Foundation For Medical Education And Research | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
| CA3031691A1 (en) * | 2016-09-13 | 2018-03-22 | Rasna Research Inc. | Dactinomycin compositions and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia |
| WO2018094309A2 (en) | 2016-11-21 | 2018-05-24 | Nant Holdings Ip, Llc | Fractal combination therapy |
| CN110248673A (zh) * | 2016-11-21 | 2019-09-17 | 百祥制药公司 | 用于治疗胰腺癌的包括SapC-DOPS的联合疗法 |
| CN110290786A (zh) * | 2016-12-21 | 2019-09-27 | 普罗米蒂克医药Smt有限公司 | 用于预防或最小化上皮细胞-间充质细胞转换的方法和组合物 |
| US11229668B2 (en) | 2017-02-07 | 2022-01-25 | Nantcell, Inc. | Maximizing T-cell memory and compositions and methods therefor |
| US20180235936A1 (en) * | 2017-02-17 | 2018-08-23 | University Of Notre Dame Du Lac | Cancer treatment methods |
| LT3589661T (lt) | 2017-03-02 | 2024-02-12 | Genentech, Inc. | Adjuvantinis her2 atžvilgiu teigiamo krūties vėžio gydymas |
| IL270132B2 (en) | 2017-04-24 | 2024-12-01 | Nantcell Inc | Neoepitope vectors and methods for them |
| US10753942B2 (en) | 2017-05-15 | 2020-08-25 | Indicator Systems International, Inc. | Methods to detect remnant cancer cells |
| WO2019018813A1 (en) | 2017-07-21 | 2019-01-24 | Varian Medical Systems, Inc. | METHODS OF USING ULTRA HIGH DOSE RATE RADIATION AND THERAPEUTIC AGENTS |
| JP7250764B2 (ja) * | 2017-08-18 | 2023-04-03 | コセラ バイオサイエンス， インコーポレイテッド | Ｔｇ０２の多形形態 |
| CN118459413A (zh) * | 2017-09-26 | 2024-08-09 | 加利福尼亚大学董事会 | 用于治疗癌症的组合物和方法 |
| AU2018360766B2 (en) | 2017-11-06 | 2024-09-19 | Rapt Therapeutics, Inc. | Anticancer agents |
| US11773187B2 (en) | 2018-01-17 | 2023-10-03 | Nantbio, Inc. | Enhanced immunogenicity for GPI-anchored antigens |
| SG11202007130RA (en) | 2018-01-26 | 2020-08-28 | Univ California | Methods and compositions for treatment of angiogenic disorders using anti-vegf agents |
| FI3758708T3 (fi) | 2018-03-01 | 2025-02-18 | Astrazeneca Ab | (2s)-{(1s)-1-syano-2-[4-(3-metyyli-2-okso-2,3-dihydro-1,3-bentsoksatsol-5-yyli)fenyyli]etyyli}-1,4-oksatsepaani-2-karboksamidia käsittäviä farmaseuttisia koostumuksia |
| RU2020134124A (ru) | 2018-03-20 | 2022-04-20 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | СПОСОБЫ ЛЕЧЕНИЯ НАРУШЕНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ ПУТЕМ ВВЕДЕНИЯ СОДЕРЖАЩИХ ИНГИБИТОР mTOR И АЛЬБУМИН НАНОЧАСТИЦ |
| AU2019247655A1 (en) | 2018-04-03 | 2020-10-01 | Vaxess Technologies, Inc. | Microneedle comprising silk fibroin applied to a dissolvable base |
| US11823773B2 (en) | 2018-04-13 | 2023-11-21 | Nant Holdings Ip, Llc | Nant cancer vaccine strategies |
| BR112020023431A2 (pt) | 2018-05-22 | 2021-02-23 | Abraxis Bioscience, Llc | métodos e composições para tratamento de hipertensão pulmonar |
| KR20210032431A (ko) | 2018-07-17 | 2021-03-24 | 인스메드 인코포레이티드 | 루푸스 신염을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드 |
| US20220226473A1 (en) * | 2018-09-30 | 2022-07-21 | Bai Yao Zhi Da (Beijing) Nanobio Technology Co., Ltd. | Nucleic acid nanocarrier drug and preparation method thereof, pharmaceutical composition and application thereof |
| EP3926047A4 (en) * | 2018-10-16 | 2023-08-09 | Bai Yao Zhi Da (Beijing) Nanobio Technology Co., Ltd. | NUCLEIC ACID DELIVERY MEDICINAL PRODUCT, PROCESS FOR ITS PREPARATION, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF |
| WO2020112868A1 (en) * | 2018-11-30 | 2020-06-04 | Aileron Therapeutics, Inc. | Combination therapy of peptidomimetic macrocycles |
| RU2706347C1 (ru) * | 2019-07-24 | 2019-11-18 | ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "РОССИЙСКИЙ НАУЧНЫЙ ЦЕНТР РАДИОЛОГИИ И ХИРУРГИЧЕСКИХ ТЕХНОЛОГИЙ ИМЕНИ АКАДЕМИКА А.М. ГРАНОВА" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ / ФГБУ "РНЦРХТ им. ак. А.М. Гранова" Минздрава России | Способ лечения операбельной аденокарциномы головки поджелудочной железы |
| CA3158764A1 (en) | 2019-10-28 | 2021-05-06 | Abraxis Bioscience, Llc | Pharmaceutical compositions of albumin and rapamycin |
| CA3168512A1 (en) | 2019-11-25 | 2021-06-03 | Napoleone Ferrara | Long-acting vegf inhibitors for intraocular neovascularization |
| WO2022178218A1 (en) | 2021-02-19 | 2022-08-25 | Mevion Medical Systems, Inc. | Gantry for a particle therapy system |
| CN114949200B (zh) * | 2021-02-20 | 2025-08-19 | 北京大学人民医院 | 全反式维a酸联合低剂量利妥昔单抗在制备治疗激素耐药或复发itp的药物中的应用 |
| WO2022232420A1 (en) * | 2021-04-29 | 2022-11-03 | Insmed Incorporated | Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cancer |
| EP4493189A1 (en) | 2022-03-14 | 2025-01-22 | Laekna Limited | Combination treatment for cancer |
| WO2023250117A2 (en) | 2022-06-24 | 2023-12-28 | Vaxess Technologies, Inc. | Applicator for medicament patch |
| EP4577212A1 (en) * | 2022-08-26 | 2025-07-02 | Ideaya Biosciences, Inc. | Methods of treating uveal melanoma |
| WO2024081674A1 (en) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
| IL321931A (en) | 2023-01-06 | 2025-09-01 | Insmed Inc | New and reversible DPP1 inhibitors and their uses |
| WO2024228964A1 (en) | 2023-04-30 | 2024-11-07 | Aadi Bioscience, Inc. | Treatments comprising an mtor inhibitor nanoparticle composition |
| WO2024243413A1 (en) | 2023-05-24 | 2024-11-28 | Aadi Bioscience, Inc. | Combination therapy with a mtor inhibitor and a multi-tyrosine kinase inhibitor for treating soft tissue sarcoma |
| AU2024313639A1 (en) | 2023-06-23 | 2025-12-04 | Vaxess Technologies, Inc. | Applicator for medicament patch |
| WO2025034870A1 (en) | 2023-08-08 | 2025-02-13 | Aadi Bioscience, Inc. | Combination of nab-sirolimus and an estrogen suppresor for use in the treatment of hormone-dependent cancers |
| WO2025049962A1 (en) | 2023-08-31 | 2025-03-06 | Aadi Bioscience, Inc. | Combination cancer treatments with a composition comprising an mtor pathway inhibitor |
| WO2025129108A1 (en) | 2023-12-14 | 2025-06-19 | Aadi Bioscience, Inc. | Methods of treating a cancer in an individual |
Family Cites Families (149)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5206018A (en) * | 1978-11-03 | 1993-04-27 | Ayerst, Mckenna & Harrison, Inc. | Use of rapamycin in treatment of tumors |
| US5470571A (en) * | 1988-01-27 | 1995-11-28 | The Wistar Institute | Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425 |
| FR2660556B1 (fr) | 1990-04-06 | 1994-09-16 | Rhone Poulenc Sante | Microspheres, leur procede de preparation et leur utilisation. |
| IL98528A0 (en) * | 1990-06-21 | 1992-07-15 | Merck & Co Inc | Pharmaceutical compositions containing hybrid for killing bladder cancer cells |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| CZ282603B6 (cs) | 1991-03-06 | 1997-08-13 | Merck Patent Gesellschaft Mit Beschränkter Haftun G | Humanizované a chimerické monoklonální protilátky |
| US6515009B1 (en) * | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US5811447A (en) * | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| CA2086874E (en) * | 1992-08-03 | 2000-01-04 | Renzo Mauro Canetta | Methods for administration of taxol |
| US6306421B1 (en) * | 1992-09-25 | 2001-10-23 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
| US5981568A (en) * | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US6491938B2 (en) * | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US5997904A (en) * | 1993-02-22 | 1999-12-07 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
| US5650156A (en) * | 1993-02-22 | 1997-07-22 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of nutriceuticals and compositions useful therefor |
| US20030073642A1 (en) * | 1993-02-22 | 2003-04-17 | American Bioscience, Inc. | Methods and formulations for delivery of pharmacologically active agents |
| US5916596A (en) * | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US5665383A (en) * | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of immunostimulating agents for in vivo delivery |
| US6749868B1 (en) * | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US5665382A (en) * | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of pharmaceutically active agents for in vivo delivery |
| US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US6528067B1 (en) | 1993-02-22 | 2003-03-04 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
| US20030133955A1 (en) * | 1993-02-22 | 2003-07-17 | American Bioscience, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US20030068362A1 (en) * | 1993-02-22 | 2003-04-10 | American Bioscience, Inc. | Methods and formulations for the delivery of pharmacologically active agents |
| US20070117862A1 (en) * | 1993-02-22 | 2007-05-24 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| AU673057B2 (en) * | 1993-02-22 | 1996-10-24 | Abraxis Bioscience, Llc | Methods for (in vivo) delivery of biologics and compositionsuseful therefor |
| US6753006B1 (en) * | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US5362478A (en) | 1993-03-26 | 1994-11-08 | Vivorx Pharmaceuticals, Inc. | Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell |
| US5886026A (en) * | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| PT1155689E (pt) * | 1993-07-19 | 2007-01-31 | Angiotech Pharm Inc | Composições anti-angiogenicas e metodos de utilização |
| US6441026B1 (en) * | 1993-11-08 | 2002-08-27 | Aventis Pharma S.A. | Antitumor compositions containing taxane derivatives |
| WO1995019171A1 (en) * | 1994-01-14 | 1995-07-20 | Cell Therapeutics, Inc. | Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf |
| US5626862A (en) * | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
| US5662883A (en) | 1995-01-10 | 1997-09-02 | Nanosystems L.L.C. | Microprecipitation of micro-nanoparticulate pharmaceutical agents |
| US5534270A (en) | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
| US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
| CA2178541C (en) * | 1995-06-07 | 2009-11-24 | Neal E. Fearnot | Implantable medical device |
| US5609629A (en) * | 1995-06-07 | 1997-03-11 | Med Institute, Inc. | Coated implantable medical device |
| US5744460A (en) * | 1996-03-07 | 1998-04-28 | Novartis Corporation | Combination for treatment of proliferative diseases |
| US6441025B2 (en) | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
| SI0932399T1 (sl) * | 1996-03-12 | 2006-10-31 | Pg Txl Co Lp | Vodotopna paklitakselna predzdravila |
| EP1208847B8 (en) * | 1996-07-30 | 2007-02-14 | Novartis AG | Pharmaceutical compositions for the treatment of transplant rejection, as well as autoimmune or inflammatory conditions |
| US20070092563A1 (en) * | 1996-10-01 | 2007-04-26 | Abraxis Bioscience, Inc. | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US6495579B1 (en) * | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
| US6143276A (en) * | 1997-03-21 | 2000-11-07 | Imarx Pharmaceutical Corp. | Methods for delivering bioactive agents to regions of elevated temperatures |
| US6884879B1 (en) * | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| EP1023050B1 (en) * | 1997-06-27 | 2013-09-25 | Abraxis BioScience, LLC | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20030199425A1 (en) * | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
| US6258084B1 (en) | 1997-09-11 | 2001-07-10 | Vnus Medical Technologies, Inc. | Method for applying energy to biological tissue including the use of tumescent tissue compression |
| GB9800569D0 (en) * | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| CN1125651C (zh) | 1998-04-16 | 2003-10-29 | 欧维塔有限公司 | 新颖的、含有存在于大高良姜中的芳族化合物与萜类化合物的协同组合物 |
| IL141155A0 (en) * | 1998-07-30 | 2002-02-10 | Human Rt | Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin |
| US6682758B1 (en) * | 1998-12-22 | 2004-01-27 | The United States Of America As Represented By The Department Of Health And Human Services | Water-insoluble drug delivery system |
| US6740665B1 (en) | 1999-02-10 | 2004-05-25 | Ramachandran Murali | Tyrosine kinase inhibitors and methods of using the same |
| US6537585B1 (en) * | 1999-03-26 | 2003-03-25 | Guilford Pharmaceuticals, Inc. | Methods and compositions for treating solid tumors |
| CA2369740A1 (en) | 1999-04-22 | 2000-11-02 | American Biosciences, Inc. | Long term administration of pharmacologically active agents |
| HK1045646A1 (zh) | 1999-05-21 | 2002-12-06 | Abraxis Bioscience, Llc | 蛋白質穩定化的藥理學活性劑，其製備方法及其使用方法 |
| MXPA01011981A (es) | 1999-05-24 | 2003-09-04 | Sonus Pharma Inc | Vehiculo de emulsion para farmacos poco solubles. |
| CA2388918A1 (en) | 1999-11-12 | 2001-05-17 | Entremed, Inc. | Methods for administration of therapeutic agents on an antiangiogenic schedule |
| US7740841B1 (en) * | 2000-01-28 | 2010-06-22 | Sunnybrook Health Science Center | Therapeutic method for reducing angiogenesis |
| IT1318401B1 (it) * | 2000-03-17 | 2003-08-25 | Indena Spa | Derivati di n-desacetiltiocolchicina e composizioni farmaceutiche cheli contengono. |
| KR20030008368A (ko) | 2000-04-10 | 2003-01-25 | 테바 파마슈티컬 인더스트리즈 리미티드 | 세포고사 유도성 화학 요법 제제의 투여에 의한 암 치료방법 및 이를 위한 조성물 |
| ITMI20001107A1 (it) * | 2000-05-18 | 2001-11-18 | Acs Dobfar Spa | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
| JP4102185B2 (ja) * | 2000-06-30 | 2008-06-18 | グラクソ グループ リミテッド | キナゾリンジトシル酸塩化合物 |
| ATE526019T1 (de) | 2000-07-28 | 2011-10-15 | Sloan Kettering Inst Cancer | Verfahren zur behandlung von zellproliferationen störungen und virusinfektionen |
| CA2422964A1 (en) | 2000-09-22 | 2002-03-28 | Bristol Myers Squibb Company | Method for reducing toxicity of combined chemotherapies |
| DE60203260T2 (de) * | 2001-01-16 | 2006-02-02 | Glaxo Group Ltd., Greenford | Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs |
| JP2004523518A (ja) | 2001-01-19 | 2004-08-05 | バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド | より効能が大きく副作用の少ない癌治療方法 |
| US6548531B2 (en) * | 2001-02-09 | 2003-04-15 | Hoffmann-La Roche Inc. | Method for cancer therapy |
| GB0103668D0 (en) * | 2001-02-15 | 2001-03-28 | Biointeractions Ltd | Methods and clinical devices for the inhibition or prevention of mammalian cell growth |
| WO2002069949A2 (en) * | 2001-03-06 | 2002-09-12 | Prendergast Patrick T | Combination therapy for reduction of toxycity of chemotherapeutic agents |
| WO2002076459A1 (en) | 2001-03-06 | 2002-10-03 | Bristol-Myers Squibb Company | Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin |
| US6752922B2 (en) * | 2001-04-06 | 2004-06-22 | Fluidigm Corporation | Microfluidic chromatography |
| US7638161B2 (en) | 2001-07-20 | 2009-12-29 | Applied Materials, Inc. | Method and apparatus for controlling dopant concentration during BPSG film deposition to reduce nitride consumption |
| US6872715B2 (en) * | 2001-08-06 | 2005-03-29 | Kosan Biosciences, Inc. | Benzoquinone ansamycins |
| US7056338B2 (en) * | 2003-03-28 | 2006-06-06 | Conor Medsystems, Inc. | Therapeutic agent delivery device with controlled therapeutic agent release rates |
| US20040033271A1 (en) * | 2001-12-03 | 2004-02-19 | Seth Lederman | Methods for contemporaneous administration of levamisole and 5-fluorouracil |
| US20040143004A1 (en) | 2002-02-26 | 2004-07-22 | Joseph Fargnoli | Metronomic dosing of taxanes |
| ITMI20020681A1 (it) * | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina |
| ITMI20020680A1 (it) * | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento |
| US20040126400A1 (en) | 2002-05-03 | 2004-07-01 | Iversen Patrick L. | Delivery of therapeutic compounds via microparticles or microbubbles |
| US7794743B2 (en) * | 2002-06-21 | 2010-09-14 | Advanced Cardiovascular Systems, Inc. | Polycationic peptide coatings and methods of making the same |
| US7038071B2 (en) | 2002-07-16 | 2006-05-02 | Sonus Pharmaceuticals, Inc. | Platinum compounds |
| JP3835763B2 (ja) | 2002-08-19 | 2006-10-18 | ファイザー・プロダクツ・インク | 増殖亢進疾患のための組み合わせ治療 |
| US20040047835A1 (en) * | 2002-09-06 | 2004-03-11 | Cell Therapeutics, Inc. | Combinatorial drug therapy using polymer drug conjugates |
| US20050158375A1 (en) * | 2002-11-15 | 2005-07-21 | Toshikiro Kimura | Pharmaceutical composition containing liposomes for treating cancer |
| US20050095267A1 (en) * | 2002-12-04 | 2005-05-05 | Todd Campbell | Nanoparticle-based controlled release polymer coatings for medical implants |
| KR20190034694A (ko) | 2002-12-09 | 2019-04-02 | 아브락시스 바이오사이언스, 엘엘씨 | 약리학적 물질의 조성물 및 그 전달방법 |
| LT1585548T (lt) | 2002-12-09 | 2018-09-25 | Abraxis Bioscience, Llc | Farmakologinių agentų kompozicijos ir įvedimo būdai |
| AU2004204778B2 (en) * | 2003-01-10 | 2008-05-22 | Threshold Pharmaceuticals, Inc. | Treatment of cancer with 2-deoxyglucose |
| KR20050119665A (ko) | 2003-03-28 | 2005-12-21 | 코산 바이오사이언시즈, 인코포레이티드 | 재발협착증을 예방하기 위한 장치, 방법 및 조성물 |
| EP1643971A2 (en) | 2003-05-22 | 2006-04-12 | Neopharm, Inc. | Liposomal formulations comprising a combination of two or more active agents |
| RS20150135A1 (sr) | 2003-05-30 | 2015-08-31 | Genentech Inc. | Tretman sa anti-vegf antitelima |
| US20050026893A1 (en) | 2003-05-30 | 2005-02-03 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants |
| AR046510A1 (es) * | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
| BRPI0414698A (pt) | 2003-09-23 | 2006-11-28 | Novartis Ag | combinação de um inibidor receptor de vegf com um agente quimioterapêutico |
| EP1673069B1 (en) | 2003-10-15 | 2016-10-12 | SynCore Biotechnology CO., LTD | Cationic liposomes comprising an active drug for use in treatment of cancer |
| US20080045559A1 (en) | 2003-10-29 | 2008-02-21 | Sonus Pharmaceuticals, Inc. | Tocopherol-modified therapeutic drug compounds |
| JP2007509978A (ja) | 2003-10-29 | 2007-04-19 | ソーナス ファーマシューティカルズ， インコーポレイテッド | トコフェロール修飾治療薬化合物 |
| US20050203174A1 (en) | 2004-03-09 | 2005-09-15 | Kosan Biosciences, Inc. | Combination therapies using leptomycin B |
| CA2560059A1 (en) | 2004-03-15 | 2005-09-29 | Sonus Pharmaceuticals, Inc. | Platinum carboxylate anticancer compounds |
| US20060003931A1 (en) * | 2004-05-06 | 2006-01-05 | Genentech, Inc. | Crystal structure of the hepatocyte growth factor and methods of use |
| US8420603B2 (en) * | 2004-05-14 | 2013-04-16 | Abraxis Bioscience, Llc | SPARC and methods of use thereof |
| MXPA06013191A (es) | 2004-05-14 | 2007-07-24 | Abraxis Bioscience Inc | Metodos de tratamiento que utilizan proteinas que enlazan albumina como objetivos. |
| CA2567520A1 (en) | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Maytansinoid-antibody conjugates |
| AU2005249205A1 (en) * | 2004-06-03 | 2005-12-15 | F. Hoffmann-La Roche Ag | Treatment with gemcitabine and an EGFR-inhibitor |
| AU2005249566B2 (en) | 2004-06-04 | 2010-11-11 | Genentech, Inc. | Method for treating multiple sclerosis |
| GT200500155A (es) | 2004-06-16 | 2006-05-15 | Terapia del càncer resistente al platino | |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| US20070166388A1 (en) | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| HUE038768T2 (hu) | 2005-02-18 | 2018-11-28 | Abraxis Bioscience Llc | Terápiás szerek kombinációi, valamint beadásukra szolgáló módszerek, és kombinációs terápia |
| EP1869077A2 (en) * | 2005-02-18 | 2007-12-26 | Abraxis BioScience, Inc. | Q3 sparc deletion mutant and uses thereof |
| EP1896007B1 (en) | 2005-05-04 | 2014-03-19 | Medigene AG | Method of administering a cationic liposomal preparation comprising paclitexel |
| US20080221135A1 (en) | 2005-05-13 | 2008-09-11 | Bristol-Myers Squibb Company | Combination therapy |
| PT1931321T (pt) * | 2005-08-31 | 2019-05-14 | Abraxis Bioscience Llc | Composições compreendendo agentes farmacêuticos pouco hidrossolúveis e agentes antimicrobianos |
| CA2620389C (en) | 2005-08-31 | 2014-06-17 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| WO2007059116A2 (en) | 2005-11-14 | 2007-05-24 | Abraxis Bioscience, Inc. | Geldanamycin derivatives and pharmaceutical compositions thereof |
| US8168216B2 (en) | 2006-03-22 | 2012-05-01 | Medigene Ag | Treatment of triple receptor negative breast cancer |
| US9037257B2 (en) * | 2006-04-07 | 2015-05-19 | Medtronic, Inc. | Resonance tuning module for implantable devices and leads |
| SG136814A1 (en) | 2006-04-12 | 2007-11-29 | Tencube Pte Ltd | System for tracking mobile equipment and associated mobile subscribersæ identity |
| US20080280987A1 (en) * | 2006-08-31 | 2008-11-13 | Desai Neil P | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
| US20100112077A1 (en) | 2006-11-06 | 2010-05-06 | Abraxis Bioscience, Llc | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
| ES2700074T3 (es) | 2006-12-14 | 2019-02-13 | Abraxis Bioscience Llc | Terapia para el cáncer de mama sobre la base del estado de los receptores hormonales con nanopartículas que comprenden taxano |
| BRPI0808635B1 (pt) | 2007-03-07 | 2022-06-07 | Abraxis Bioscience, Llc | Uso de uma composição farmacêutica compreendendo nanopartículas que compreendem rapamicina ou um seu derivado e uma proteína veículo, composição para uso em um método de tratamento de câncer em um indivíduo, forma de dosagem unitária para o referido tratamento, e kit |
| WO2008137148A2 (en) | 2007-05-03 | 2008-11-13 | Abraxis Bioscience, Llc | Methods and compositions for treating pulmonary hypertension |
| ES2435452T3 (es) | 2007-06-01 | 2013-12-19 | Abraxis Bioscience, Llc | Métodos y composiciones para tratar un cáncer recurrente |
| WO2009009587A2 (en) | 2007-07-09 | 2009-01-15 | Board Of Regents Of The University Of Nebraska | Apoptosis-modulating protein therapy for proliferative disorders and nanoparticles containing the same |
| WO2009126401A1 (en) | 2008-04-10 | 2009-10-15 | Abraxis Bioscience, Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
| AU2009324464B2 (en) | 2008-12-11 | 2016-05-05 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| WO2010105172A1 (en) | 2009-03-13 | 2010-09-16 | Abraxis Bioscience, Llc | Combination therapy with thiocolchicine derivatives |
| US20130195983A1 (en) | 2009-04-10 | 2013-08-01 | Neil P. Desai | Nanoparticle formulations and uses thereof |
| RS59896B1 (sr) | 2009-04-15 | 2020-03-31 | Abraxis Bioscience Llc | Kompozicije nanočestica bez priona i postupci povezani sa njima |
| KR20120053052A (ko) | 2009-08-25 | 2012-05-24 | 아브락시스 바이오사이언스, 엘엘씨 | 헤지호그 억제제 및 탁산의 나노입자 조성물로의 조합 요법 |
| CN104784121A (zh) | 2010-03-26 | 2015-07-22 | 阿布拉科斯生物科学有限公司 | 治疗肝细胞癌的方法 |
| BR112012024590A2 (pt) | 2010-03-29 | 2016-05-31 | Abraxis Bioscience Inc | métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos |
| US9393318B2 (en) | 2010-03-29 | 2016-07-19 | Abraxis Bioscience, Llc | Methods of treating cancer |
| EP2563393B1 (en) | 2010-04-26 | 2016-06-08 | Abraxis BioScience, LLC | Sparc binding antibodies and uses thereof |
| MY188911A (en) | 2010-06-02 | 2022-01-13 | Abraxis Bioscience Llc | Methods of treating bladder cancer |
| KR20130088116A (ko) | 2010-06-04 | 2013-08-07 | 아브락시스 바이오사이언스, 엘엘씨 | 췌장암의 치료 방법 |
| JP6031437B2 (ja) | 2010-06-07 | 2016-11-24 | アブラクシス バイオサイエンス， エルエルシー | 増殖性疾患を処置するための組み合わせ療法 |
| KR102108959B1 (ko) | 2011-04-28 | 2020-05-11 | 아브락시스 바이오사이언스, 엘엘씨 | 나노입자 조성물의 혈관내 전달 및 그의 용도 |
| WO2013090634A1 (en) | 2011-12-14 | 2013-06-20 | Abraxis Bioscience, Llc | Use of polymeric excipients for lyophilization or freezing of particles |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| US20140199405A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
| US20140199404A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on level of a nucleoside transporter |
-
2006
- 2006-02-21 HU HUE10011106A patent/HUE038768T2/hu unknown
- 2006-02-21 CN CN2013100757784A patent/CN103169729A/zh active Pending
- 2006-02-21 NZ NZ560879A patent/NZ560879A/en unknown
- 2006-02-21 MX MX2007009960A patent/MX2007009960A/es active IP Right Grant
- 2006-02-21 LT LTEP10011106.1T patent/LT2301531T/lt unknown
- 2006-02-21 PL PL06735710T patent/PL1853250T3/pl unknown
- 2006-02-21 KR KR1020167013205A patent/KR101764375B1/ko active Active
- 2006-02-21 SG SG201007821-0A patent/SG166775A1/en unknown
- 2006-02-21 KR KR1020137034986A patent/KR20140016402A/ko not_active Ceased
- 2006-02-21 EP EP20154548.0A patent/EP3698783A1/en not_active Withdrawn
- 2006-02-21 JP JP2007556407A patent/JP5769358B2/ja active Active
- 2006-02-21 AT AT06735710T patent/ATE531365T1/de active
- 2006-02-21 AU AU2006213999A patent/AU2006213999B2/en active Active
- 2006-02-21 KR KR1020197012570A patent/KR20190062506A/ko not_active Ceased
- 2006-02-21 LT LTEP17165979.0T patent/LT3248600T/lt unknown
- 2006-02-21 BR BRPI0607809-5A patent/BRPI0607809A2/pt not_active Application Discontinuation
- 2006-02-21 RU RU2007134571/15A patent/RU2452482C2/ru active
- 2006-02-21 ZA ZA200707491A patent/ZA200707491B/xx unknown
- 2006-02-21 NZ NZ595313A patent/NZ595313A/xx unknown
- 2006-02-21 DK DK17165979.0T patent/DK3248600T3/da active
- 2006-02-21 KR KR1020187031184A patent/KR101976003B1/ko active Active
- 2006-02-21 US US11/359,286 patent/US8034375B2/en active Active
- 2006-02-21 PT PT171659790T patent/PT3248600T/pt unknown
- 2006-02-21 KR KR1020207009782A patent/KR20200038337A/ko not_active Ceased
- 2006-02-21 PT PT06735710T patent/PT1853250E/pt unknown
- 2006-02-21 MX MX2011009748A patent/MX339142B/es unknown
- 2006-02-21 KR KR1020157009103A patent/KR101625347B1/ko active Active
- 2006-02-21 PT PT100111061T patent/PT2301531T/pt unknown
- 2006-02-21 SI SI200632377T patent/SI3248600T1/sl unknown
- 2006-02-21 SI SI200631217T patent/SI1853250T1/sl unknown
- 2006-02-21 ES ES10011106.1T patent/ES2678448T3/es active Active
- 2006-02-21 DK DK06735710.3T patent/DK1853250T3/da active
- 2006-02-21 HU HUE17165979A patent/HUE049789T2/hu unknown
- 2006-02-21 ES ES06735710T patent/ES2375828T3/es active Active
- 2006-02-21 CA CA2598239A patent/CA2598239C/en active Active
- 2006-02-21 KR KR1020177021183A patent/KR101914254B1/ko active Active
- 2006-02-21 PL PL17165979T patent/PL3248600T3/pl unknown
- 2006-02-21 CA CA3054535A patent/CA3054535A1/en not_active Abandoned
- 2006-02-21 MX MX2015016754A patent/MX383644B/es unknown
- 2006-02-21 CN CN2006800116779A patent/CN101160123B/zh active Active
- 2006-02-21 EP EP17165979.0A patent/EP3248600B8/en not_active Revoked
- 2006-02-21 SI SI200632272T patent/SI2301531T1/sl unknown
- 2006-02-21 EP EP06735710A patent/EP1853250B1/en not_active Revoked
- 2006-02-21 ES ES17165979T patent/ES2802541T3/es active Active
- 2006-02-21 DK DK10011106.1T patent/DK2301531T3/en active
- 2006-02-21 WO PCT/US2006/006167 patent/WO2006089290A1/en not_active Ceased
- 2006-02-21 CN CN2013102337091A patent/CN103285395A/zh active Pending
- 2006-02-21 CN CN201510411744.7A patent/CN105288630A/zh active Pending
- 2006-02-21 EP EP10011106.1A patent/EP2301531B1/en active Active
- 2006-02-21 PL PL10011106T patent/PL2301531T3/pl unknown
- 2006-02-21 KR KR1020077021327A patent/KR20070114753A/ko not_active Ceased
- 2006-02-21 CA CA2902071A patent/CA2902071C/en active Active
- 2006-10-06 US US11/544,242 patent/US8257733B2/en active Active
-
2007
- 2007-07-20 US US11/880,314 patent/US7780984B2/en active Active
- 2007-08-15 IL IL185288A patent/IL185288A/en active IP Right Grant
-
2008
- 2008-12-12 US US12/334,115 patent/US7758891B2/en active Active
-
2011
- 2011-09-08 US US13/228,323 patent/US8268348B2/en active Active
-
2012
- 2012-01-05 CY CY20121100013T patent/CY1112907T1/el unknown
- 2012-02-22 RU RU2012106620A patent/RU2632103C2/ru active
- 2012-06-21 IL IL220547A patent/IL220547A0/en unknown
- 2012-07-12 JP JP2012156721A patent/JP2012193205A/ja not_active Withdrawn
- 2012-08-01 US US13/564,633 patent/US20130195922A1/en not_active Abandoned
- 2012-08-14 US US13/585,696 patent/US9101543B2/en active Active
-
2013
- 2013-01-09 JP JP2013001664A patent/JP2013064014A/ja not_active Withdrawn
- 2013-02-25 US US13/776,481 patent/US20140023717A1/en not_active Abandoned
- 2013-02-25 US US13/776,484 patent/US20140017315A1/en not_active Abandoned
-
2014
- 2014-06-18 LU LU92484C patent/LU92484I2/xx unknown
- 2014-06-19 CY CY2014023C patent/CY2014023I1/el unknown
- 2014-08-25 US US14/468,127 patent/US20150079177A1/en not_active Abandoned
- 2014-09-05 JP JP2014180852A patent/JP6092824B2/ja active Active
-
2015
- 2015-04-30 JP JP2015092577A patent/JP6513467B2/ja active Active
-
2016
- 2016-10-07 JP JP2016198882A patent/JP6685875B2/ja active Active
-
2017
- 2017-06-06 IL IL252715A patent/IL252715A0/en unknown
- 2017-10-18 US US15/787,586 patent/US20180169017A1/en not_active Abandoned
-
2018
- 2018-03-19 JP JP2018050735A patent/JP2018090643A/ja active Pending
- 2018-07-20 CY CY20181100760T patent/CY1120445T1/el unknown
-
2019
- 2019-10-28 JP JP2019195457A patent/JP2020012005A/ja not_active Withdrawn
-
2020
- 2020-04-02 IL IL273765A patent/IL273765A/en unknown
- 2020-06-25 CY CY20201100579T patent/CY1123110T1/el unknown